Broadcom
AVGO
Taiwan Semiconductor
TSM
Tesla
TSLA
ASML Holding
ASML
Qualcomm
QCOM
US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 28.890
- -0.140-0.48%
Close Dec 13 16:00 ET
- 28.890
- 0.0000.00%
Post 17:19 ET
2.02BMarket Cap-7.64P/E (TTM)
29.255High28.250Low720.35KVolume28.550Open29.030Pre Close20.72MTurnover1.31%Turnover RatioLossP/E (Static)69.80MShares37.00052wk High2.73P/B1.59BFloat Cap15.32052wk Low--Dividend TTM54.93MShs Float58.380Historical High--Div YieldTTM3.46%Amplitude7.520Historical Low28.759Avg Price1Lot Size
About Akero Therapeutics Company
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Company Profile
SymbolAKRO
Company NameAkero Therapeutics
Listing DateJun 20, 2019
Issue Price16.00
Founded2017
CEODr. Andrew Cheng, M.D.,PhD
MarketNASDAQ
Employees56
Fiscal Year Ends12-31
Address601 Gateway Boulevard,Suite 350
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080-7006
Phone1-650-487-6488
Websitehttp://www.akerotx.com
Company Executives
- Name
- Position
- Salary
- Dr. Andrew Cheng, M.D.,PhD
- President, Chief Executive Officer and Director
- 8.83M
- Dr. Timothy Rolph, D.Phil.
- Chief Scientific Officer
- 3.49M
- Dr. Jonathan Young, J.D.
- Executive Vice President, Chief Operating Officer and Secretary
- 3.44M
- William R. White, J.D.
- Principal Accounting Officer, Executive Vice President, Treasurer, Chief Financial Officer and Head, Corporate Development
- 4.29M
- Catriona Yale
- Chief Development Officer
- 3.45M
- Patrick Lamy
- Senior Vice President, Commercial Strategy
- --
- Mark T. Iwicki
- Chairman of the Board
- 606.06K
- Dr. Seth L. Harrison, M.D.
- Independent Director
- 568.56K
- Dr. Graham Waley, M.D.,PhD
- Independent Director
- 578.56K
- Jane Pritchett Henderson
- Independent Director
- 586.06K
- Dr. Yuan Xu, PhD
- Independent Director
- 573.56K
- Dr. Judy Chou, PhD
- Independent Director
- 571.06K
- Tomas J. Heyman
- Independent Director
- 581.06K
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.